Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Director Carol Giltner Gallagher sold 1,184 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $14.20, for a total value of $16,812.80. Following the sale, the director now owns 110,105 shares in the company, valued at approximately $1,563,491. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Atara Biotherapeutics, Inc. (NASDAQ ATRA) traded up $0.10 on Friday, reaching $14.60. The company had a trading volume of 165,671 shares, compared to its average volume of 180,411. Atara Biotherapeutics, Inc. has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). analysts expect that Atara Biotherapeutics, Inc. will post -4 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Carol Giltner Gallagher Sells 1,184 Shares of Atara Biotherapeutics, Inc. (ATRA) Stock” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://theolympiareport.com/2017/11/19/carol-giltner-gallagher-sells-1184-shares-of-atara-biotherapeutics-inc-atra-stock.html.

Several research firms recently issued reports on ATRA. Jefferies Group LLC reiterated a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $20.00 target price on shares of Atara Biotherapeutics in a report on Friday, October 6th. Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Monday, August 7th. ValuEngine upgraded Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Atara Biotherapeutics has a consensus rating of “Hold” and a consensus price target of $24.40.

A number of hedge funds and other institutional investors have recently made changes to their positions in ATRA. Eagle Asset Management Inc. increased its position in Atara Biotherapeutics by 17.8% during the second quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock worth $20,901,000 after buying an additional 225,367 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Atara Biotherapeutics by 617.9% during the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after buying an additional 173,184 shares during the last quarter. Neuberger Berman Group LLC increased its position in Atara Biotherapeutics by 15.2% during the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after buying an additional 147,061 shares during the last quarter. Morgan Stanley increased its position in Atara Biotherapeutics by 147.6% during the first quarter. Morgan Stanley now owns 175,058 shares of the biotechnology company’s stock worth $3,597,000 after buying an additional 104,369 shares during the last quarter. Finally, Artal Group S.A. increased its position in Atara Biotherapeutics by 20.0% during the third quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $9,930,000 after buying an additional 100,000 shares during the last quarter. 82.52% of the stock is currently owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.